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INTRODUCTION
Dengue is a viral disease which leads to considerable
morbidity and mortality (Balasubramanian et al., 2019; Dighe
et al., 2019). The dengue virus (DENV), one of the most rapidly
spreading mosquito-borne viral pathogens in the tropical
and subtropical regions of the world, is a member of the
genus Flavivirus (family Flaviviridae). The DENV is transmitted
to humans via the bite of infected Aedes aegypti and Aedes
albopictus mosquitos. This virus causes a wide spectrum of
infections ranging from a non-severe form, the dengue fever
(DF), to more severe forms such as dengue haemorrhagic
fever (DHF) and dengue shock syndrome (DSS) (Mir et al.,
2016; Weng et al., 2017; Perera et al., 2018; Balasubramanian
et al., 2019; Rozera et al., 2019). There are five distinct, yet
closely related, stereotypes of the DENV which include DENV-
1, DENV-2, DENV-3, DENV-4, DENV-5 with DENV-2 being the most
prevalent among the five (de Sousa et al., 2015; Mir et al.,
2016; Aguilera-Pesantes et al., 2017; Singh & Rawat, 2017;
Weng et al., 2017; Perera et al., 2018).
The NS2B/NS3 protease is a two component non-
structural protein in the genomic sequence of the DENV. This
enzyme mediates the cleavage of polyproteins which sub-
sequently releases functional proteins that are required for
the production of mature DENV and for maintaining its
infectivity. Hence, it can be concluded that the NS2B/NS3
protease plays an important role in the genome replication
process of the DENV. The NS2B/NS3 protease is therefore an
ideal target for drug discovery against dengue infection (de
Sousa et al., 2015; Timiri et al., 2016; Aguilera-Pesantes et al.,
2017; Takagi et al., 2017; Weng et al., 2017).
A large number of medicinal plants have been used to
alleviate dengue infection. As a result, the secondary
metabolites derived from these plants could be potential
sources of dengue antiviral agents. To date, flavonoids,
chalcones, biflavonoids, phenolics, alkaloids and curcuminoids
have been reported to inhibit the DENV-2 NS2B/NS3 protease
(Abd Kadir et al., 2013; Abubakr et al., 2013; Teixeira et al., 2014;
de Sousa et al., 2015; Mir et al., 2016; Timiri et al., 2016; Singh
& Rawat, 2017; Perera et al., 2018; Balasubramanian et al.,
2019; Dighe et al., 2019).
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The NS2B/NS3 protease is crucial for the pathogenesis of the DENV. Therefore, the inhibition
of this protease is considered to be the key strategy for the development of new antiviral
drugs. In the present study, malabaricones C (3) and E (4), acylphenols from the fruits of
Myristica cinnamomea King, have been respectively identified as moderate (27.33 ± 5.45 μM)
and potent (7.55 ± 1.64 μM) DENV-2 NS2B/NS3 protease inhibitors, thus making this the first
report on the DENV-2 NS2B/NS3 protease inhibitory activity of acylphenols. Based on the
molecular docking studies, compounds 3 and 4 both have π-π interactions with Tyr161. While
compound 3 has hydrogen bonding interactions with Gly151, Gly153 and Tyr161, compound 4
however, forms hydrogen bonds with Ser135, Asp129, Phe130 and Ile86 instead. The results
from the present study suggests that malabaricones C (3) and E (4) could be employed as
lead compounds for the development of new dengue antivirals from natural origin.
Keywords: Myristica cinnamomea King; acylphenols; malacaricone C; malabaricone E; DENV-2
NS2B/NS3 protease.
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In search of new small molecule scaffolds as lead
compounds for the inhibition of the DENV-2 NS2B/NS3
protease, we decided to investigate the inhibiting potential
of acylphenols. Herein, we report on the isolation of
malabaricones A–C (1–3) and E (4) from the fruits of Myristica
cinnamomea King (Figure 1). Their structures were characterized
by means of NMR and MS spectral analyses. These acylphenols
were subsequently evaluated for their DENV-2 NS2B/NS3
protease inhibitory activity. Following this, molecular docking
was performed in order to provide insights into the binding
interactions between the most promising acylphenol(s) and
the DENV-2 NS2B/NS3 protease.
MATERIALS AND METHODS
General experimental procedures
Analytical and preparative TLC was carried out on Merck 60
F254 silica gel plates (absorbent thickness: 0.25 and 0.50 mm,
respectively) (Merck, Germany). Column chromatography (CC)
was performed using silica gel (230-400 mesh, ASTM) (Merck,
Germany) and Sephadex LH-20 (Sigma-Aldrich, USA). IR
spectra were recorded using a Perkin-Elmer Spectrum 400
FT-IR Spectrometer. NMR spectra were acquired in CD3OD
(Merck, Germany) using a JOEL ECA 400 MHz NMR Spectrometer.
LCMS-IT-TOF spectra were obtained using an Agilent 6530
Accurate-Mass Q-TOF LC/MS system. UV spectra were recorded
using a Shimadzu 1650 PC UV-V is Spectrophotometer. All
solvents were of analytical grade and were distilled prior to
use. DMSO and Tris-HCl buffer were respectively purchased
from Merck (Germany) and Sigma-Aldrich (USA) while Boc-
Gly-Arg-Arg-MCA was purchased from Peptide Institute, Inc
(Japan).
Plant Material
M. cinnamomea was collected from Johor in 2003. The plant
was identified by Mr. Teo Leong Eng and a voucher specimen
(KL 5043) has been deposited with the University of Malaya
herbarium.
Isolation and characterization of compounds 1-4
Dried powdered fruits (1.5 kg) of M. cinnamomea were
extracted with ethyl acetate (5.0 L, 2x) at room temperature,
yielding 262.99 g of extract. The ethyl acetate extract (30 g)
was chromatographed on a silica gel column (625 g, 7.2 cm x
63 cm). Elution was carried out using mixtures of dichloro-
methane : acetone in proportions of 90:10 (v/v, 3 L), 85:15
(v/v, 5 L), 80:20 (v/v, 5 L) and 75:25 (v/v, 3 L) sequentially
to afford fractions FA (5.73 g), FB (2.44 g), FC (8.50 g) and FD
(6.25 g), respectively. FA was fractionated on a silica gel
column (180 g, 2.5 cm x 72 cm), eluted using dichloromethane
(2 L) to afford sub-fraction FA 1 (3.24 g), following which FA 1
was re-chromatographed over a Sephadex LH-20 column
(25 g) using methanol (1 L) as the eluent to afford 1 (2.70 g).
FB was subjected to column chromatography over 60 g of
silica gel (2.5 cm x 64.5 cm) with an isocratic solvent system
of dichloromethane : acetone (95:5 v/v, 1 L) to provide sub-
fraction FB 1 (1.86 g). FB 1 was further purified by passing it
through a Sephadex LH-20 column (25 g) with methanol (500
mL) to yield 2 (1.29 g). Column chromatography of FC over
silica gel (270 g, 5.0 cm x 72 cm) to afford sub-fraction FC 1
(6.50 g) was achieved using dichloromethane : acetone (90:10
v/v, 1 L). Next, the purification of FC 1 to provide 3 (5.18 g) was
carried out over a Sephadex LH-20 column (25 g) using
methanol (1 L) as the eluting solvent. Column chromatography
of FD over silica gel (180 g, 2.5 cm x 72 cm) with successive
elutions using dichloromethane : acetone in ratios of (85:15
v/v, 300 mL) and (80:20 v/v, 500 mL) afforded sub-fractions FD
1 (3.14 g) and FD 2 (1.25 g), respectively. FD 1 was re-
chromatographed over a silica gel column (120 g, 2.5 cm x 72
cm) with an isocratic solvent system of dichloromethane :
acetone (80:20 v/v, 1.5 L) to give sub-fractions FD 1.1 (0.09 g),
FD 1.2 (0.08 g) and FD 1.3 (1.05 g). FD 1.2 was purified over a
Sephadex LH-20 column (25 g) using methanol (500 mL) as
the eluent to afford sub-fraction FD 1.2.1 (0.02 g) which was
later purified via repetitive preparative TLC with dichloro-
methane : acetone [75:25 v/v] to yield 4 (4.6 mg). The degree
of the purity of the isolated compounds was determined by
1H NMR spectroscopy and was found to be 98%-99% pure.
Malabaricone A (1)
Pale yellow amorphous powder. UV (MeOH): 342 (3.07), 269
(3.67), 214 (3.78). IR (NaCl): 3583, 3271, 2920, 2851, 1714, 1589,
1511.  1H-NMR (CD3OD, 400 MHz): 7.23 (2H, m, H-12 & H-14), 7.21
(1H, t, J = 8.0, H-19), 7.17 (2H, m, H-11 & H-15), 7.12 (1H, m, H-13),
6.34 (2H, d, J = 8.0, H-18 & H-20), 3.10 (2H, t, J = 8.0, H-2), 2.58 (2H,
t, J = 8.0, H-9), 1.66 (2H, brt, J = 8.0, H-3), 1.58 (2H, brt, J = 8.0, H-
8), 1.33 (8H, brs, H-4-H-7). 13C-NMR (CD3OD, 400 MHz): 209.8 (C-
1), 163.5 (C-17 & C-21), 144.1 (C-10), 136.9 (C-19), 129.5 (C-11 & C-
15), 129.4 (C-12 & C-14), 126.7 (C-13), 111.5 (C-16), 108.5 (C-18 &
C-20), 45.9 (C-2), 37.1 (C-9), 32.9 (C-8), 30.7 (C-4), 30.6 (C-5 & C-6),
Figure 1. Structures of compounds 1-4.
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30.4 (C-7). 25.9 (C-3). LC/MS-IT-TOF: 349.1774 ([M + Na]+; calc,
C21H26O3Na 349.1774).
Malabaricone B (2)
Yellow amorphous powder. UV (MeOH): 341 (2.83), 270 (3.46),
206 (3.56). IR (NaCl): 3584, 3339, 2927, 2854, 1708, 1596, 1514.
1H-NMR (CD3OD, 400 MHz): 7.17 (1H, t, J = 8.0, H-19), 6.96 (2H, d,
J = 8.0, H-11 & H-15), 6.67 (2H, d, J = 8.0, H-12 & H-14), 6.33 (2H,
d, J = 8.0 Hz, H-18 & H-20), 3.10 (2H, t, J = 8.0, H-2), 2.47 (2H, t, J
= 8.0, H-9), 1.66 (2H, p, J = 8.0, H-3), 1.56 (2H, p, J = 8.0, H-8), 1.31
(8H, brs, H-4-H-7). 13C-NMR (CD3OD, 400 MHz): 209.8 (C-1), 163.5
(C-17 & C-21), 156.3 (C-13), 137.0 (C-19), 135.0 (C-10), 130.4 (C-11
& C-15), 116.1 (C-12 & C-14), 111.5 (C-16), 108.5 (C-18 & C-20),
45.9 (C-2), 36.2 (C-9), 33.2 (C-8), 30.7 (C-4), 30.6 (C-5), 30.4 (C-6
& C-7), 25.9 (C-3). LC/MS-IT-TOF: 365.1717 ([M + Na]+; calc.
C21H26O4Na 365.1723).
Malabaricone C (3)
Yellow amorphous powder. UV (MeOH): 338 (2.80), 269 (3.36),
222 (3.50), 204 (3.70). IR (NaCl): 3583, 3343, 2927, 2854, 1714,
1589, 1516. 1H-NMR (CD3OD, 400 MHz): 7.17 (1H, t, J = 8.0, H-19),
6.33 (2H, d, J = 8.0, H-18 & H-20), 6.65 (1H, d, J = 8.0, H-14), 6.60
(1H, d, J = 8.0, H-11), 6.46 (1H, dd, J = 8.0, 1.8, H-15), 3.10 (2H, t,
J = 8.0, H-2), 2.43 (2H, t, J = 8.0, H-9), 1.65 (2H, p, J = 8.0, H-3), 1.53
(2H, brt, J = 8.0, H-8), 1.31 (8H, brs, H-4-H-7). 13C-NMR (CD3OD,
400 MHz): 209.8 (C-1), 163.5 (C-17 & C-21), 146.1 (C-12), 144.1
(C-13), 137.0 (C-19), 136.0 (C-10), 120.8 (C-15), 116.6 (C-11), 116.3
(C-14), 111.5 (C-16), 108.5 (C-18 & C-20), 45.9 (C-2), 36.4 (C-9),
33.1 (C-8), 30.7 (C-4), 30.5 (C-5 & C-6), 30.4 (C-7), 25.9 (C-3).
LC/MS-IT-TOF: 359.1860 ([M + H]+; calc. C21H27O5 359.1853).
Malabaricone E (4)
Yellow amorphous powder. UV (MeOH): 341 (2.83), 270 (3.46),
224 (3.67). IR (NaCl): 3583, 3272, 2924, 2853, 1611, 1515. 1H-NMR
(CD3OD, 400 MHz): 6.97 (2H, d, J = 8.0, H-11 & H-15), 6.67 (2H, d,
J = 8.0, H-12 & H-14), 5.80 (2H, s, H-18 & H-20), 3.02 (2H, t, J = 8.0
Hz, H-2), 2.50 (2H, t, J = 8.0 Hz, H-9), 1.64 (2H, p, J = 8.0 Hz, H-3),
1.55 (2H, brt, J = 8.0, H-8), 1.33 (8H, brs, H-4-H-7). 13C-NMR (CD3OD,
400 MHz): 207.6 (C-1), 166.5 (C-19), 165.9 (C-17 & C-21), 156.3
(C-13), 135.0 (C-10), 130.3 (C-11 & C-15), 116.1 (C-12 & C-14),
105.0 (C-16), 95.8 (C-18 & C-20), 44.9 (C-2), 36.2 (C-9), 33.2 (C-8),
30.9 (C-4), 30.6 (C-5 & C-6), 30.4 (C-7), 26.3 (C-3). LC/MS-IT-TOF:
381.1675 ([M + Na]+; calc. C21H26O5Na 381.1672).
Expression and purification of the DENV-2 NS2B/NS3 protease
The DENV-2 NS2B/NS3 protease was expressed and purified
according to the method described by Hariono et al. (2019).
DENV-2 NS2B/NS3 protease inhibition assay
The in vitro protease inhibition assay was carried out using
purified DENV-2 NS2B/NS3 protease as the enzyme and Boc-
Gly-Arg-Arg-MCA as the substrate according to the method
previously described by our group (Salleh et al., 2019). The
concentration of the enzyme and the substrate were 0.5 μM
and 10mM, respectively in 200 mM of Tris-HCl buffer (pH 8.5)
while the concentration of the inhibitor was 200 μg/mL. All
of the tests were performed in quadruplicates. Firstly, the
Tris-HCl buffer (pH 8.5) was pipetted into the wells, followed
by 1 μL of the inhibitor and 3.1 μL of the enzyme. Before
adding the substrate, the enzyme and the inhibitor were
incubated at 37°C for 10 minutes. After adding the substrate,
the reaction mixture was incubated at 37°C for 60 minutes.
All of the reactions were performed in 96-well plates with a
final volume of 100 μL per well. Fluorescence was detected
using a Promega Glomax Multi Detection System microplate
reader with the excitation and emission wavelengths at 365
and 410-460 nm, respectively. In order to determine the IC50
values, the same protocol was used as described above with
serial dilutions of the inhibitors with concentrations in the
range of 1.5625 to 200 μg/mL.
Molecular docking
Molecular docking was performed using AutoDock4.2 along
with AutoDockTools (ADT) following the method described
by Hariono et al. (2019) with some modifications (Hariono et
al., 2019; Morris et al., 2009). The protein was prepared as
described by Hariono et al. (2019) whereby the DENV-2 NS2B/
NS3pro model was built based on the DENV-2 complex
cofactor-protease homology model using the crystal structure
of the NS2B/NS3pro West Nile Virus (WNV) in complex with
peptidic inhibitor and DENV-2 NS2B/NS3pro apoprotein as
the template (Hariono et al., 2019; Wichapong et al., 2010).
The structures of the compounds were constructed and
energy minimization was performed using Hyperchem 8.0
(HyperChem (TM), Profesional 8.0, Hypercube, Inc). The
minimized structures of the ligand and the protein were
subjected to molecular docking using AutoDock4.2. Polar
hydrogen and Kollman charges were added to the protein.
For the ligands, the non-polar hydrogen atoms were merged
and Gasteiger charges were assigned. A grid box with a
dimension of 60 × 60 × 60 and with a grid spacing of 0.375 Å
was positioned around the catalytic triad with the centre set
at x = 21.517, y = 43.428 and z = -1.743. The dockings were
carried out with the Lamarckian Genetics Algorithm (GA)
search program applied to generate 250 runs. The conforma-
tion with the lowest binding energy in the most populated
cluster was selected. The conformations from the docking
experiments were analyzed and visualized using Discovery
Studio 3.5 (www.accelrys.com).
RESULTS AND DISCUSSION
Preliminary screening of the ethyl acetate and methanol
extracts of the fruits of M. cinnamomea at a concentration of
200 μg/mL proved that the extracts were potential inhibitors
(96.69% and 70.43%, respectively) of the DENV-2 NS2B/NS3
protease. The ethyl acetate extract was subsequently
subjected to repeated silica gel column chromatography,
Sephadex LH-20 and preparative thin layer chromatography
to yield four acylphenols, identified as malabaricone A (1),
malabaricone B (2), malabaricone C (3) and malabaricone E
(4) (S1) upon comparison of their spectroscopic data with
those previously reported by our group (Abdul Wahab et al.,
2016; Sivasothy et al., 2016; Othman et al., 2019).
The initial DENV-2 NS2B/NS3 protease inhibitory
activities of compounds 1–4 were assayed at 200 μg/mL
(Table 1). Since compounds 3 and 4 exhibited more that 70%
inhibition towards the DENV-2 NS2B/NS3 protease, these
compounds were further evaluated in order to determine







3 98.54 27.33 ± 5.45
4 99.91 7.55 ± 1.64
Quercetin (standard) – 10.48 ± 2.14
a Data presented as Mean ± SD (n = 4).
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their respective IC50 values. The IC50 values of compounds 3
and 4 along with the reference standard employed in this
study are summarized in Table 1. Compounds 3 (27.33 ± 5.45
μM) and 4 (7.55 ± 1.64 μM) both inhibited the DENV-2 NS2B/
NS3 protease with the latter being the stronger inhibitor
among the two and around 1.5 times more potent than that
of quercetin (10.48 ± 2.14 μM) itself.
Based on the molecular docking studies (Table 2, Figures
2 and 3) the inhibition of the DENV-2 NS2B/NS3 protease by
compound 4 was probably due to the hydrogen bonding
interactions between the following functional groups in
compound 4 and the acid amino residues in the protease:
hydroxyl group at C-17 and the oxygen atom of the carbonyl
group (C-1) with Ser 135 of the catalytic triad, between the
hydroxyl group at C-19 with Asp129 and Phe130 in the S1 pocket
and between the hydroxyl group at C-13 with Ile86 in the S3
pocket. In addition, there was also a π-π interaction between
ring A with Tyr161 in the S1 pocket. As for compound 3, the
hydroxyl groups at C-13 and C-17 formed hydrogen bonds with
Gly151 while that of C-12 formed hydrogen bonds with not
only Gly151 but with Tyr161 in the S1 pocket and Gly153 as
well. The π-π interaction between ring A with Tyr161 in the S1
pocket was also observed. The aforementioned interactions
could have contributed to the activity of compound 3 (Table
2, Figures 2 and 3).
Table 2. Binding interaction data for compounds 3 and 4 with amino acid residues of the NS2B/NS3 protease
Ligand/Compound
Binding Energy
Residue Type of Interaction Distance (Å) C10
(kcal/mol)
Malabaricone C (3) -5.47 Gly153 Hydrogen 2.23 Hydroxyl group (OH) at C-12
Gly151 Hydrogen 2.16 Hydroxyl group (OH) at C-12
2.08 Hydroxyl group (OH) at C-13
2.03 Hydroxyl group (OH) at C-17
Tyr161 Hydrogen 2.39 Hydroxyl group (OH) at C-12
π-π – Aromatic ring A
Malabaricone E (4) -5.89 Ser135 Hydrogen 2.02 Carbonyl group at C-1
Hydrogen 1.80 Hydroxyl group (OH) at C-17
Phe130 Hydrogen 2.40 Hydroxyl group (OH) at C-19
Hydrogen 2.33 Hydroxyl group (OH) at C-19
Asp129 Hydrogen 1.96 Hydroxyl group (OH) at C-19
Ile86 Hydrogen 2.18 Hydroxyl group (OH) at C-13
Tyr161 π-π – Aromatic ring A
Figure 2. Visualization of malabaricone C (3) and malabaricone E (4) at the binding site of the NS2B/NS3 protease where
the protein structures are represented by solid ribbon style.
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Figure 3. Simpliûed view of the binding interaction between malabaricone C (3) and malabaricone E (4) with the amino
acid residues of the NS2B/NS3 protease. The hydrogen bonding of the ligands with the amino acid residues are shown in
green dotted lines.
Upon comparison of the docking results obtained for
both compounds, compound 4 was found to have a slightly
lower binding energy (-5.89 kcal/mol) as compared to
compound 3 (-5.47 kcal/mol) (Table 2). The catalytic triad of
the DENV-2 NS2B/NS3 protease is made up of the His51, Asp75
and Ser135 amino acid residues and only compound 4 was
found to have a hydrogen bonding interaction with Ser135
(Hariono et al., 2019; Yin et al., 2006). Furthermore, the formation
of a hydrogen bond with Asp129 was only observed for
compound 4. Asp129 which is located at the bottom of the S1
pocket is an important amino acid residue as a previous
study has revealed that it is the key interaction for the
substrate recognition in the S1 pocket of the protein (Frecer
& Miertus, 2010). Hence, it would be reasonable to postulate
that the above two interactions between compound 4 and
the protease could be the reason behind the higher potency
of compound 4 as compared to compound 3 towards the
inhibition of the DENV-2 NS2B/NS3 protease.
CONCLUSIONS
Little is known about the potential usage of the genus
Myristica in the treatment of dengue apart from a recent paper
by Rosmalena et al. (2019). Rosmalena and her co-workers
reported that the methanolic extract of M. fatua Houtt var.
magnifica (Bedd.) Sinclair at a concentration of 20μg/mL was
found to actively inhibit (122.7%) the DENV-2 NGC strain
without any cytotoxic effect (Rosmalena et al., 2019; Cao et al.,
2013; Herath and Padmasiri, 1999; Herath and Priyadarshani,
1996; Herath and Priyadarshini, 1997; Maia et al., 2008; Pham
et al., 2002).
The potent inhibitory activity of the ethyl acetate extract
towards the DENV-2 NS2B/NS3 protease in the current
investigation has provided scientific evidence for the
possible usage of the fruits of M. cinnamomea to treat dengue.
Moreover, since malabaricone C (3) which has been identified
as a moderate inhibitor of the DENV-2 NS2B/NS3 protease is
ubiquitous in many members of the genus Myristica, i.e M.
fragrans, M. malabarica, M. fatua, M. crassa, M. gigantea, M.
maingayi and M. maxima, therefore this makes the genus
Myristica a promising and valuable source of dengue
antivirals. On this basis, the in vitro, in vivo and in silico studies
of compound 3 should be further investigated to facilitate
the understanding of its mechanism of inhibition and to
evaluate its effectiveness as an antiviral drug.
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